Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication ALIMTA ® is a folate analog metabolic inhibitor indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC. FDA label
Also known as TTFields, Pemetrexed, Alimta, Electric fields
NovoTTF-100L · 2 trials · 3 indications
PFS will be measured from the date of enrollment to date of progression (in months) based on RANO citeria.
| Arm | Type | Description |
|---|---|---|
| Experimental: TTFields | EXPERIMENTAL | Patients receive continuous TTFields treatment using the Optune® System with high intensity transducer arrays. |
| A | EXPERIMENTAL | Treatment with concomitant Alimta and NovoTTF-100L |
| Name | Type | Description |
|---|---|---|
| TTFields | DEVICE | TTFields treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine. Other Names: • TTFields |
| NovoTTF-100L | DEVICE | TTFields treatment 12h/d for the duration of the study (until progression)concomitant to standard Alimta dosing |
Inclusion Criteria: 1. Histologically confirmed diagnosis of GBM according to WHO classification criteria. 2. Age ≥ 18 years 3. Not a candidate for further radiotherapy or additional resection of residual tumor. 4. Patients with first or second radiological disease progression per RANO criteria doc...
Top 20 of 90 competitors
NovoTTF-100L is an investigational device being studied for the treatment of Non-small Cell Lung Cancer (NSCLC). It delivers tumor treating fields, a type of electric field therapy, to the tumor region. In a completed Phase 1 clinical trial, it was evaluated in combination with the chemotherapy drug pemetrexed (Alimta) for advanced NSCLC.
NovoTTF-100L is developed by NovoCure Limited, a company traded on the NASDAQ under the ticker symbol NVCR. NovoCure specializes in tumor treating fields therapy, and NovoTTF-100L is one of its investigational devices being studied for oncology applications.
NovoTTF-100L is in Phase 1 clinical development. It is an investigational device and has not been approved by regulatory authorities. A Phase 1 trial has been completed, but the device remains in early-stage clinical investigation for Non-small Cell Lung Cancer.
NovoTTF-100L has been studied in one completed Phase 1 clinical trial, identified as NCT00749346. This trial evaluated NovoTTF-100L in combination with pemetrexed (Alimta) for advanced Non-small Cell Lung Cancer. The trial enrolled 42 participants and was conducted in Switzerland.
NovoTTF-100L works by delivering tumor treating fields, which are low-intensity electric fields that disrupt cancer cell division. This mechanism is intended to inhibit tumor growth. The device is applied externally and is being studied in combination with chemotherapy for Non-small Cell Lung Cancer.